These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Chemotherapy for good-risk germ cell tumors: current concepts and controversies.
    Author: Vaughn DJ.
    Journal: Urol Clin North Am; 2007 May; 34(2):171-7; abstract viii-ix. PubMed ID: 17484922.
    Abstract:
    Through a series of well-designed randomized clinical trials, the treatment of patients with cisplatin-based chemotherapy has evolved such that approximately 90% of patients who have good-risk metastatic germ cell tumor (GCT) will be cured of their disease. At present, first-line chemotherapy for patients who have good-risk metastatic GCT is three cycles of bleomycin/etoposide/cisplatin. An alternative to this is four cycles of etoposide/cisplatin. This article examines the progress that has been made in the development of chemotherapy for good-risk metastatic GCT and raises questions for further consideration and investigation.
    [Abstract] [Full Text] [Related] [New Search]